Kytril (granisetron) 1 mg tablets and infusion concentrate information, including composition, dosage, warnings and storage.
Kytril® (granisetron hydrochloride) is supplied as film‑coated tablets (1 mg or 2 mg) and as a concentrate for solution for infusion (1 mg/1 ml or 3 mg/3 ml). The leaflet details the active substance, excipients, pharmaceutical form and strength of each dosage form.
The document provides indications for chemotherapy‑induced, radiotherapy‑induced and postoperative nausea and vomiting, recommended adult and pediatric dosing regimens, contraindications, warnings, drug interactions, pharmacokinetic properties, stability requirements and handling instructions for preparation of infusion solutions.
| Form | Film‑coated tablets |
|---|---|
| Strength (tablet) | 1 mg granisetron per tablet |
| Infusion concentrate strength | 1 mg/1 ml (also 3 mg/3 ml) |
| Storage (tablets) | Do not store above 30 °C |
| Storage (ampoules) | Room temperature (15–25 °C), do not freeze |
Oral: one tablet once daily during and up to a week after chemotherapy. Intravenous (patients >50 kg): one 3 mg/3 ml ampoule diluted in 20–50 ml infusion solution, administered over 5 minutes before therapy.
Remove the required volume of Kytril solution (1 ml for 1 mg or 3 ml for 3 mg) and dilute with 20–50 ml of an appropriate intravenous solution such as 0.9 % sodium chloride, 0.18 % sodium chloride with 4 % dextrose, 5 % dextrose, Hartmann’s solution, sodium lactate or mannitol.